Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fennec Pharmaceuticals Inc (NQ: FENC )

8.580 +0.250 (+3.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 72,321
Open 8.429
Bid (Size) 8.340 (1)
Ask (Size) 9.000 (10)
Prev. Close 8.330
Today's Range 8.380 - 8.765
52wk Range 5.265 - 10.85
Shares Outstanding 26,419,511
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Recap: Fennec Pharmaceuticals Q1 Earnings
 
Via Benzinga
Earnings Outlook For Fennec Pharmaceuticals
 
Via Benzinga

Performance

YTD
-14.46%
-14.46%
1 Month
+7.92%
+7.92%
3 Month
-4.35%
-4.35%
6 Month
-10.06%
-10.06%
1 Year
+51.86%
+51.86%

More News

Read More
Analyst Ratings for Fennec Pharmaceuticals
Via Benzinga
7 Biotech Stocks Sitting in the Sweet Spot
Via InvestorPlace
US Stocks Open Lower; Dow Dips 250 Points
Via Benzinga
Expert Ratings for Fennec Pharmaceuticals
Via Benzinga
What 4 Analyst Ratings Have To Say About Fennec Pharmaceuticals
Via Benzinga
4 Analysts Have This to Say About Fennec Pharmaceuticals
Via Benzinga
Where Fennec Pharmaceuticals Stands With Analysts
Via Benzinga
After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss
Via Benzinga
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Via Benzinga
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
NASDAQ:FENC Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Fennec Pharmaceuticals Inc.
Via SBWire
U.S. FDA accepts Fennec Pharma's New Drug Application (NDA) Resubmission for PEDMARK
Via Benzinga
NASDAQ:FENC Shareholder Notice: Deadline on April 11, 2022 in Lawsuit Against Fennec Pharmaceuticals Inc.
Via SBWire
FENC Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Last Few Hours to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
FENC FINAL DEADLINE APRIL 11: NATIONALLY RANKED ROSEN LAW FIRM Encourages Fennec Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Monday Deadline in Securities Class Action - FENC
Via NewMediaWire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)
From The Law Offices of Frank R. Cruz
Via Business Wire
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Fennec Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FENC
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Via Benzinga
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Fennec Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FENC
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Fennec Pharmaceuticals Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - FENC
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Investor Notice: Lawsuit Alleges Violations of Securities Laws
Via SBWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.